MEDICLINIC INTERNATIONAL PLC - Chief Executive Officer to continue as a Non-executive Director

Chief Executive Officer to continue as a Non-executive Director

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)

24 May 2018

Chief Executive Officer to continue as a Non-executive Director

Mediclinic, a leading international private healthcare services group, announces that on 23
May 2018, the Board agreed that, subject to Mr Danie Meintjes’ re-election as a director of the
Company at the Annual General Meeting to be held on 25 July 2018, he will continue to serve
as an executive director until 31 July 2018 and as a non-executive director with effect from 1
August 2018. As previously announced on 29 March 2018, Dr Ronnie van der Merwe will
succeed Mr Meintjes as Chief Executive Director on 1 June 2018.

Mediclinic’s chairman, Dr Edwin Hertzog commented:
“Danie’s continued role as a non-executive director of the Company after his retirement as
CEO was made after careful consideration by the Nomination Committee and the Board. This
appointment is considered to be in the long-term interest of Mediclinic, its shareholders and
other stakeholders in view of the wealth of knowledge and experience Danie has gained in
different capacities over 30 years at Mediclinic.”

NOTES TO EDITORS
About Danie Meintjes
Mr Meintjes (aged 61) joined the group in 1985 as the Hospital Manager of Mediclinic
Sandton before being appointed head of Human Resources and Training for the Mediclinic
Group. He subsequently became a member of Mediclinic International Limited’s Executive
Committee in 1995 and a director in 1996. Seconded to the Mediclinic’s operations in Dubai in
2006 and appointed as the Chief Executive Officer of Mediclinic Middle East in 2007, he was
named Chief Executive Officer of Mediclinic International Limited in 2010. Following the
combination of the businesses of the Company (then Al Noor Hospitals Group plc)
and Mediclinic International Limited, Mr Meintjes continued to serve as the Chief Executive
Officer of the enlarged group since February 2016.

About Mediclinic International plc
Mediclinic is an international private healthcare services group with operating divisions in
Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its
core purpose is to enhance the quality of life of patients by providing acute care, specialist-
orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in
Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care
facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern
Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in
Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6
hospitals and 22 clinics with more than 700 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with
secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 24/05/2018 08:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.